MX351274B - Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis. - Google Patents

Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis.

Info

Publication number
MX351274B
MX351274B MX2013011692A MX2013011692A MX351274B MX 351274 B MX351274 B MX 351274B MX 2013011692 A MX2013011692 A MX 2013011692A MX 2013011692 A MX2013011692 A MX 2013011692A MX 351274 B MX351274 B MX 351274B
Authority
MX
Mexico
Prior art keywords
solid oral
inhibitor
crystalline forms
oral formulations
apoptosis protein
Prior art date
Application number
MX2013011692A
Other languages
English (en)
Spanish (es)
Inventor
Thakur Jeewan
Yang Dong
Feng Lili
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42937834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX351274(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX351274B publication Critical patent/MX351274B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013011692A 2009-08-12 2010-08-11 Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis. MX351274B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27405109P 2009-08-12 2009-08-12
PCT/EP2010/061679 WO2011018474A1 (en) 2009-08-12 2010-08-11 Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein

Publications (1)

Publication Number Publication Date
MX351274B true MX351274B (es) 2017-10-06

Family

ID=42937834

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013011692A MX351274B (es) 2009-08-12 2010-08-11 Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis.
MX2012001844A MX2012001844A (es) 2009-08-12 2010-08-11 Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012001844A MX2012001844A (es) 2009-08-12 2010-08-11 Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis.

Country Status (24)

Country Link
US (4) US8623385B2 (enExample)
EP (1) EP2464644A1 (enExample)
JP (3) JP2013501751A (enExample)
KR (2) KR20180020315A (enExample)
CN (2) CN102471331B (enExample)
AR (1) AR077869A1 (enExample)
AU (4) AU2010283748A1 (enExample)
BR (1) BR112012003118A2 (enExample)
CA (1) CA2769616A1 (enExample)
CL (1) CL2012000349A1 (enExample)
CO (1) CO6612189A2 (enExample)
IL (1) IL217760A0 (enExample)
IN (1) IN2012DN00858A (enExample)
MA (1) MA33511B1 (enExample)
MX (2) MX351274B (enExample)
MY (1) MY160475A (enExample)
PE (2) PE20121132A1 (enExample)
PH (1) PH12014501890A1 (enExample)
RU (1) RU2671196C1 (enExample)
SG (1) SG177713A1 (enExample)
TN (1) TN2012000026A1 (enExample)
TW (1) TWI607006B (enExample)
WO (1) WO2011018474A1 (enExample)
ZA (1) ZA201200390B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017253560B2 (en) 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119060A1 (en) * 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
AU2003249920A1 (en) 2002-07-02 2004-01-23 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
AU2005231956B2 (en) 2004-04-07 2009-11-05 Novartis Ag Inhibitors of IAP
KR101278732B1 (ko) 2004-12-20 2013-07-09 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
PE20110224A1 (es) 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO

Also Published As

Publication number Publication date
EP2464644A1 (en) 2012-06-20
PE20170777A1 (es) 2017-07-04
MA33511B1 (fr) 2012-08-01
US20170081319A1 (en) 2017-03-23
US8623385B2 (en) 2014-01-07
AU2014213533A1 (en) 2014-09-04
AU2016203145A1 (en) 2016-06-02
KR20180020315A (ko) 2018-02-27
US20140093570A1 (en) 2014-04-03
RU2012108931A (ru) 2013-09-27
KR20120048008A (ko) 2012-05-14
WO2011018474A8 (en) 2011-09-22
AR077869A1 (es) 2011-09-28
JP2016179976A (ja) 2016-10-13
IL217760A0 (en) 2012-03-29
CN105646471A (zh) 2016-06-08
AU2010283748A1 (en) 2012-02-09
TW201118091A (en) 2011-06-01
ZA201200390B (en) 2012-10-31
SG177713A1 (en) 2012-02-28
PH12014501890B1 (en) 2015-09-14
CO6612189A2 (es) 2013-02-01
US10093665B2 (en) 2018-10-09
MX2012001844A (es) 2012-02-29
US20120128742A1 (en) 2012-05-24
JP2018172403A (ja) 2018-11-08
TWI607006B (zh) 2017-12-01
RU2671196C1 (ru) 2018-10-30
US9540363B2 (en) 2017-01-10
AU2017254950A1 (en) 2017-11-23
CN102471331B (zh) 2016-01-13
IN2012DN00858A (enExample) 2015-07-10
WO2011018474A1 (en) 2011-02-17
AU2017254950B2 (en) 2018-09-20
PH12014501890A1 (en) 2015-09-14
CL2012000349A1 (es) 2012-09-07
JP2013501751A (ja) 2013-01-17
CN102471331A (zh) 2012-05-23
TN2012000026A1 (en) 2013-09-19
PE20121132A1 (es) 2012-09-04
CA2769616A1 (en) 2011-02-17
US20180370960A1 (en) 2018-12-27
BR112012003118A2 (pt) 2016-02-23
MY160475A (en) 2017-03-15

Similar Documents

Publication Publication Date Title
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
MX2011003473A (es) Composiciones para el cuidado bucal.
MY166653A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
MY157017A (en) Sulfonamide derivatives
MX2010003866A (es) Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
TN2010000203A1 (en) Beta-lactamase inhibitors
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
PH12014500053A1 (en) Proteasome inhibitors
MX2010003864A (es) Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
IN2012DN03310A (enExample)
WO2010002956A3 (en) Heterocyclic derivatives as modulators of ion channels
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2011011109A (es) Formulaciones orales de bendamustina.
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
UA99787C2 (en) Lactams as beta secretase inhibitors
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
MX2010003563A (es) Inhibidores de proteina cinasa de c-met.
PH12014501890A1 (en) Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX343234B (es) Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.
MX2011012524A (es) Inhibidores de proteina cinasa c-met.
PT2435443E (pt) Inibidores à base de aminopirazole triazolotiadiazole da proteína quinase c met
MX2011012522A (es) Inhibidores de pirazol sustituido de proteina cinasa c-met.